

# Jason R Young

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/168211/publications.pdf>

Version: 2024-02-01

37  
papers

582  
citations

759233

12  
h-index

642732

23  
g-index

37  
all docs

37  
docs citations

37  
times ranked

487  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2054-2071.	3.0	116
2	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. <i>Haematologica</i> , 2020, 105, 348-357.	3.5	105
3	International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. <i>Blood</i> , 2022, 139, 2601-2621.	1.4	63
4	<sup>18</sup> F-FDG PET/CT in Erdheim-Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker. <i>Journal of Nuclear Medicine</i> , 2018, 59, 774-779.	5.0	46
5	Frequency and Characteristics of Nodal and Deltoid FDG and <sup>11</sup> C-Choline Uptake on PET Performed After COVID-19 Vaccination. <i>American Journal of Roentgenology</i> , 2021, 217, 1206-1216.	2.2	30
6	Efficacy of BRAF-Inhibitor Therapy in <i>BRAF</i> <i>V600E</i> -Mutated Adult Langerhans Cell Histiocytosis. <i>Oncologist</i> , 2020, 25, 1001-1004.	3.7	25
7	Rheumatoid pulmonary nodules: clinical and imaging features compared with malignancy. <i>European Radiology</i> , 2019, 29, 1684-1692.	4.5	22
8	How We Do It: A Multidisciplinary Approach to <sup>177</sup> Lu DOTATATE Peptide Receptor Radionuclide Therapy. <i>Radiology</i> , 2021, 298, 261-274.	7.3	21
9	Single-agent cladribine as an effective frontline therapy for adults with Langerhans cell histiocytosis. <i>American Journal of Hematology</i> , 2021, 96, E146-E150.	4.1	21
10	Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival. <i>American Journal of Hematology</i> , 2021, 96, 1604-1610.	4.1	18
11	Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT. <i>Journal of Hematology and Oncology</i> , 2022, 15, 36.	17.0	17
12	Analysis and impact of a multidisciplinary lymphoma virtual tumor board. <i>Leukemia and Lymphoma</i> , 2020, 61, 3351-3359.	1.3	14
13	Unusual manifestations of diffuse-type tenosynovial giant cell tumor in two patients: importance of radiologic-pathologic correlation. <i>Skeletal Radiology</i> , 2020, 49, 483-489.	2.0	10
14	Skeletal Metastasis Evaluation. <i>PET Clinics</i> , 2019, 14, 103-120.	3.0	9
15	Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?. <i>Leukemia and Lymphoma</i> , 2020, 61, 318-327.	1.3	9
16	Low-dose vemurafenib monotherapy in <i>BRAF</i> <sup>V600E</sup> -mutated Erdheim-Chester disease. <i>Leukemia and Lymphoma</i> , 2020, 61, 2733-2737.	1.3	9
17	Sustained, complete response to pexidartinib in a patient with <i>CSF1R</i> -mutated Erdheim-Chester disease. <i>American Journal of Hematology</i> , 2022, 97, 293-302.	4.1	9
18	Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis. <i>American Journal of Hematology</i> , 2021, 96, E298-E301.	4.1	7

#	ARTICLE	IF	CITATIONS
19	Clinical and therapeutic implications of BRAF fusions in histiocytic disorders. Blood Cancer Journal, 2022, 12, .	6.2	7
20	Safety and Efficacy of Percutaneous Image-Guided Mediastinal Mass Core-Needle Biopsy. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 1100-1108.	2.4	4
21	Testicular <sup>18</sup> F-FDG PET/CT uptake threshold in aggressive lymphomas. American Journal of Hematology, 2021, 96, E81-E83.	4.1	3
22	<sup>18</sup> F-FDG PET/CT of hepatocellular adenoma subtypes and review of literature. Abdominal Radiology, 2021, 46, 2604-2609.	2.1	3
23	Metabolic PET/CT Analysis of Aggressive Non-Hodgkin Lymphoma Prior to Axicabtagene Ciloleucl CAR-T Infusion: Predictors of Progressive Disease, Survival, and Toxicity. Blood, 2021, 138, 2518-2518.	1.4	3
24	Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience. Oncologist, 2022, 27, 144-148.	3.7	3
25	Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis. Blood Cancer Journal, 2022, 12, .	6.2	3
26	Computed tomographically guided transthoracic biopsy of a cardiac mass in the right ventricular outflow tract. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, e115-e118.	0.8	2
27	Radiolocalization of atypical lesions for intraoperative identification: technical factors, localization quality, success rates, patient safety, and spectrum of applications. World Journal of Surgical Oncology, 2019, 17, 88.	1.9	1
28	Efficacy of Cobimetinib in Rosai-Dorfman Disease. Blood, 2021, 138, 1506-1506.	1.4	1
29	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. Blood Cancer Journal, 2022, 12, 78.	6.2	1
30	Phenotypes and prognostic factors in adults with Langerhans cell histiocytosis.. Journal of Clinical Oncology, 2021, 39, 7049-7049.	1.6	0
31	<i>BRAF</i> <sup>V600E</sup> frequency and impact on outcomes in adults with langerhans cell histiocytosis.. Journal of Clinical Oncology, 2021, 39, 7050-7050.	1.6	0
32	The association of incidental positron emission tomography uptake in the esophagus to gastroesophageal reflux disease. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	0
33	Thoracic positron emission tomography: F-fluorodeoxyglucose and beyond. Journal of Thoracic Disease, 2020, 12, 6978-6991.	1.4	0
34	Classical and Non-Classical Phenotypes of Erdheim-Chester Disease: Correlating Clinical, Radiographic, and Genotypic Findings. Blood, 2021, 138, 2566-2566.	1.4	0
35	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. Blood, 2021, 138, 2508-2508.	1.4	0
36	Multimodality imaging of cardiac involvement in Erdheim-Chester disease. European Heart Journal Cardiovascular Imaging, 2022, , .	1.2	0

#	ARTICLE	IF	CITATIONS
37	Combined modality therapy for early-stage Hodgkin lymphoma in the PET era: A real-world study.. Journal of Clinical Oncology, 2022, 40, e19532-e19532.	1.6	0